Lerociclib is under clinical development by EQRx and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData, Phase I drugs for Castration-Resistant Prostate Cancer (CRPC) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lerociclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lerociclib overview
lerociclib is under development for the treatment of estrogen-receptor positive, hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer, castrate-resistant prostate cancer and non-small cell lung cancer (NSCLC). The drug candidate is administered through oral route. It acts by targeting cyclin-dependent kinases (CDK) 4 and 6.
It was under development for the treatment of endometrial cancer.
EQRx overview
EQRx is a biotechnology company that focuses on creating novel patent-protected medicines at lower prices. The company’s pipeline products include Aumolertinib is for the treatment of adult patients with locally advanced or metastatic NSCLC, Lerociclib is for the treatment of retinoblastoma protein (Rb) positive cancers, Nofazinlimab for the treatment of liver cancer, EQ121 for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis, Sugemalima is for the treatment of Stage IV NSCLC or ENKTL, respectively in the United States. EQRx is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Lerociclib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.